GB0008928D0 - A method of administering an antitumour compound - Google Patents

A method of administering an antitumour compound

Info

Publication number
GB0008928D0
GB0008928D0 GBGB0008928.4A GB0008928A GB0008928D0 GB 0008928 D0 GB0008928 D0 GB 0008928D0 GB 0008928 A GB0008928 A GB 0008928A GB 0008928 D0 GB0008928 D0 GB 0008928D0
Authority
GB
United Kingdom
Prior art keywords
administering
antitumour compound
antitumour
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0008928.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Priority to GBGB0008928.4A priority Critical patent/GB0008928D0/en
Publication of GB0008928D0 publication Critical patent/GB0008928D0/en
Priority to AU54769/01A priority patent/AU5476901A/en
Priority to PCT/EP2001/003765 priority patent/WO2001076597A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
GBGB0008928.4A 2000-04-11 2000-04-11 A method of administering an antitumour compound Ceased GB0008928D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0008928.4A GB0008928D0 (en) 2000-04-11 2000-04-11 A method of administering an antitumour compound
AU54769/01A AU5476901A (en) 2000-04-11 2001-04-03 A method of administering an antitumour compound
PCT/EP2001/003765 WO2001076597A2 (en) 2000-04-11 2001-04-03 A method of administering an antitumour compound using a polymer-camptothecin conjugate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0008928.4A GB0008928D0 (en) 2000-04-11 2000-04-11 A method of administering an antitumour compound

Publications (1)

Publication Number Publication Date
GB0008928D0 true GB0008928D0 (en) 2000-05-31

Family

ID=9889704

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0008928.4A Ceased GB0008928D0 (en) 2000-04-11 2000-04-11 A method of administering an antitumour compound

Country Status (3)

Country Link
AU (1) AU5476901A (en)
GB (1) GB0008928D0 (en)
WO (1) WO2001076597A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070008710A (en) 2004-04-27 2007-01-17 웰스테트 바이올로직스 코포레이션 Cancer treatment using viruses and camptothecins
MX2007015407A (en) 2005-07-14 2008-02-19 Wellstat Biologics Corp Cancer treatment using viruses, fluoropyrimidines and camptothecins.
CN108135917B (en) 2015-09-25 2021-07-09 Zy医疗 Pharmaceutical formulations based on particles comprising polysaccharide-vitamin conjugates

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9320781D0 (en) * 1993-10-08 1993-12-01 Erba Carlo Spa Polymer-bound camptothecin derivatives
GB9721070D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Bioactive derivatives of camptothecin
GB9721069D0 (en) * 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
GB9915180D0 (en) * 1999-06-29 1999-09-01 Pharmacia & Upjohn Spa Antitumour compound

Also Published As

Publication number Publication date
WO2001076597A3 (en) 2002-05-16
WO2001076597A2 (en) 2001-10-18
AU5476901A (en) 2001-10-23

Similar Documents

Publication Publication Date Title
HUP0301164A3 (en) Method of administering bisphosphonates
HRP20030383A2 (en) Lactam compound
GB0010957D0 (en) Compound & method
AU6128301A (en) Method of administering a bisphosphonate
AU2432102A (en) Lactam compound
HUP0203682A3 (en) Method for administering a phosphodiesterase 4 inhibitor
GB2366639B (en) Method of comparing parts
AU2002361357A8 (en) Method for monosulphonylation of an aminobenzofuran compound
HK1048112B (en) Process for the preparation of a 3-vinylcephem compound
GB0008928D0 (en) A method of administering an antitumour compound
SI1591122T1 (en) Method of administering bisphosphonates
GB0029420D0 (en) Method of linerising a signal
EP1357928A4 (en) A novel pharmaceutical compound and methods of making and using same
PL334221A1 (en) Method of obtaining a gamma-lactamic compound
GB0007637D0 (en) Antitumour compound
GB0006741D0 (en) Antitumour compound
GB0010572D0 (en) A set of parts
GB0003396D0 (en) A set of parts
GB0113781D0 (en) Compound
GB9915180D0 (en) Antitumour compound
GB0106570D0 (en) A set of parts
TW476347U (en) Structure of cover-in-cover for placement barrel
AUPR663501A0 (en) A method of administering a gm-csf antagonist
IL155928A0 (en) A novel pharmaceutical compound and methods of making and using same
TW450087U (en) Improved structure of machine assembly for medicine porduction machine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)